Publications by authors named "J L Pinaquy"
Article Synopsis
- - Hepatocellular carcinoma (HCC) is a major global health issue, being one of the most common cancers and a leading cause of cancer deaths, with intra-arterial therapies like TACE and SIRT being key treatment options for non-resectable cases.
- - TACE is typically used for patients with stage B HCC, while SIRT has shown promising results in patients previously treated with TACE, despite not having an official role in treatment guidelines.
- - A study involving 23 patients indicated that SIRT post-TACE resulted in a 73.8% objective response rate, with 56.5% achieving complete response, highlighting SIRT's potential effectiveness despite the complications associated with TACE.
Article Synopsis
- The study investigates the calculation of yttrium-90 microspheres activity essential for selective internal radiotherapy (SIRT).
- Using dosimetry software, researchers analyzed the absorbed doses to both tumors and healthy liver tissue before and after treatment phases.
- Results indicated significant correlations in dose distribution and suggested that optimizing microsphere dosages could enhance treatment effectiveness for some patients while reducing it for others.
Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma.
Diagn Interv Imaging
July 2022
Purpose: The purpose of this study was to evaluate the capabilities of radiomics using magnetic resonance imaging (MRI) data in the assessment of treatment response to yttrium transarterial radioembolization (TARE) in patients with locally advanced hepatocellular carcinoma (HCC) by comparison with predictions based on European Association for the Study of the Liver (EASL) criteria.
Patients And Methods: Twenty-two patients with HCC (19 men, 3 women; mean age: 66.7 ± 9.
Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France.
Cardiovasc Intervent Radiol
January 2022
Primary Objective: Recently, selective internal radiation therapy using yttrium-90 (Y90) glass microspheres (TheraSphere™) was approved for reimbursement by health authorities in France. The PROACTIF study aims to gather data on effectiveness, patient quality of life, and safety with use of Y90 glass microspheres in real-world clinical settings in France.
Inclusion Criteria: Patient with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCC), and/or metastatic colorectal cancer (mCRC) who was treated with a dose of Y90 glass microspheres that has been reimbursed in France and who do not oppose use of their personal medical data.